NCT03663400View on ClinicalTrials.gov

Identify Predictors That Distinguish Between Tofacitinib Responders and Non-responders Based on Genotype and Cellular and Molecular Profiles From Pinch Biopsies, Blood and Stool Samples

CompletedOBSERVATIONAL

Enrollment

Participants

Timeline

Start Date

December 4, 2018

Primary Completion Date

March 24, 2022

Study Completion Date

March 24, 2022

Conditions

Ulcerative Colitis

Interventions

DIAGNOSTIC_TEST

GWAS analysis by Illumina BeadChip

will generate comprehensive genotype data for patients. Samples will be used for transcriptional profiling, microbiota profiling by 16S analysis and immunological profiling by flow cytometry

Trial Locations (1)

10016

New York University School of Medicine, New York

All Listed Sponsors

lead

NYU Langone Health

OTHER

NCT03663400 - Identify Predictors That Distinguish Between Tofacitinib Responders and Non-responders Based on Genotype and Cellular and Molecular Profiles From Pinch Biopsies, Blood and Stool Samples | Biotech Hunter | Biotech Hunter